Literature DB >> 27513848

Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents.

Yang Zhang1, Yan Cao1, George L Shih1, Elizabeth M Hecht1, Martin R Prince1.   

Abstract

Purpose To explore the extent of signal hyperintensity in the brain on unenhanced T1-weighted magnetic resonance (MR) images with increasing gadolinium-based contrast agent (GBCA) doses in patients who received 35 or more linear GBCA administrations. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective study, picture archiving and communication systems of two tertiary referral hospitals were searched to identify patients who received 35 or more linear GBCA administrations. Unenhanced T1-weighted images of the brain in patients after six, 12, and 24 GBCA administrations and after the final GBCA administration were independently reviewed by three radiologists to identify sites where T1 signal intensity was increasing. Areas identified by all three observers as increasing in T1 signal intensity when compared with baseline images were further analyzed with a quantitative region of interest analysis measuring the rate of signal increase per injection and the total change after 24 linear GBCA administrations relative to reference tissues that did not show T1 shortening. Results Qualitative analysis of 13 patients with 39-59 linear GBCA administrations showed visually detectable T1 shortening in the dentate nucleus (n = 13), globus pallidus (n = 13), substantia nigra (n = 13), posterior thalamus (n = 12), red nucleus (n = 10), colliculi (n = 10), superior cerebellar peduncle (n = 7), caudate nucleus (n = 4), whole thalamus (n = 3), and putamen (n = 2). Quantitative analysis enable confirmation of signal intensity increases on unenhanced T1-weighted images relative to reference tissues in the dentate nucleus (0.53% signal intensity increase per injection, P < .001), globus pallidus (0.23% increase, P = .009), posterior thalamus (0.26% increase, P < .001), substantia nigra (0.25% increase, P = .01), red nucleus (0.25% increase, P = .01), cerebellar peduncle (0.19% increase, P = .001), and colliculi (0.21% increase, P = .02). Conclusion Increased signal intensity on unenhanced T1-weighted images was seen in the posterior thalamus, substantia nigra, red nucleus, cerebellar peduncle, colliculi, dentate nucleus, and globus pallidus. © RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27513848     DOI: 10.1148/radiol.2016152864

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  33 in total

1.  Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans.

Authors:  Olga Minaeva; Ning Hua; Erich S Franz; Nicola Lupoli; Asim Z Mian; Chad W Farris; Audrey M Hildebrandt; Patrick T Kiernan; Laney E Evers; Allison D Griffin; Xiuping Liu; Sarah E Chancellor; Katharine J Babcock; Juliet A Moncaster; Hernan Jara; Victor E Alvarez; Bertrand R Huber; Ali Guermazi; Lawrence L Latour; Ann C McKee; Jorge A Soto; Stephan W Anderson; Lee E Goldstein
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

2.  Do we need gadolinium-based contrast medium for brain magnetic resonance imaging in children?

Authors:  Dennis Dünger; Matthias Krause; Daniel Gräfe; Andreas Merkenschlager; Christian Roth; Ina Sorge
Journal:  Pediatr Radiol       Date:  2018-04-06

Review 3.  Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Authors:  Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2021-04-19

Review 4.  Distribution and chemical forms of gadolinium in the brain: a review.

Authors:  Tomonori Kanda; Yudai Nakai; Akifumi Hagiwara; Hiroshi Oba; Keiko Toyoda; Shigeru Furui
Journal:  Br J Radiol       Date:  2017-09-28       Impact factor: 3.039

Review 5.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

6.  Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis.

Authors:  Soenke Langner; Marie-Luise Kromrey; Jens-Peter Kuehn; Matthias Grothe; Martin Domin
Journal:  Eur Radiol       Date:  2017-03-13       Impact factor: 5.315

Review 7.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

8.  Quantitative Susceptibility Mapping Is Superior to T1-weighted Imaging for Detecting and Measuring Gadolinium.

Authors:  Yi Wang; Martin R Prince
Journal:  Radiology       Date:  2020-07-21       Impact factor: 11.105

Review 9.  Gadolinium-based contrast agents in children.

Authors:  Michael N Rozenfeld; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2018-08-04

Review 10.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.